TB-500
Synthetic Fragment of Thymosin Beta-4 — Tissue Repair & Recovery
Overview & Background
TB-500 is a synthetic peptide derived from the naturally occurring protein Thymosin Beta-4 (Tβ4), a ubiquitous intracellular protein found in virtually all human and animal cells. While full-length Thymosin Beta-4 is a 43-amino acid protein, TB-500 specifically corresponds to the active actin-binding domain — a shorter fragment (17 amino acids) that retains the primary biological activities of the full protein. This synthetic fragment has become one of the most widely used peptides in athletic recovery and regenerative medicine research circles.
Thymosin Beta-4 was originally isolated from thymic tissue in the 1960s and named for its source. However, subsequent research revealed it is expressed in virtually all nucleated cells and plays fundamental roles in cell migration, differentiation, and survival. Its most critical function is sequestering G-actin monomers within cells, regulating the dynamic assembly and disassembly of actin filaments that form the cytoskeleton — the structural scaffolding essential for cell movement, wound closure, and tissue remodeling.
In the context of injury and recovery, TB-500's ability to promote cell migration, reduce inflammation, and accelerate extracellular matrix remodeling has generated significant interest among athletes, military personnel, and individuals recovering from musculoskeletal injuries. Anecdotal reports of rapid recovery from tendon injuries, muscle tears, and joint damage have driven substantial off-label use, while formal clinical development has progressed more slowly due to the complexity of demonstrating efficacy in heterogeneous injury populations.
Clinical Research & Evidence
Clinical research on TB-500 (the synthetic fragment) and Thymosin Beta-4 (the full protein) has advanced through several phases. RegeneRx Biopharmaceuticals has conducted the most formal clinical trials, investigating Thymosin Beta-4 in dry eye disease (Phase 2, demonstrating improvement in corneal staining and symptoms), neurosensory recovery after cardiac surgery, and wound healing. The dry eye results were particularly encouraging, establishing proof-of-concept for the regenerative potential of this peptide class in human tissues.
Preclinical research in animal models has been more extensive and provides the mechanistic foundation for many of the recovery claims. Studies in rodent and equine models have demonstrated that Thymosin Beta-4/TB-500 accelerates healing of tendon injuries, reduces scar formation, promotes angiogenesis (new blood vessel formation) in ischemic tissue, protects cardiac muscle from ischemia-reperfusion injury, and reduces neuroinflammation following brain injury. The consistency of these findings across multiple animal species and tissue types provides biological plausibility for the anecdotal human reports.
It is important to distinguish between the robust animal evidence, the limited but positive human trial data, and the extensive but uncontrolled anecdotal reports from athletes and patients. The leap from preclinical success to proven human efficacy in musculoskeletal injury — the primary use case for TB-500 in the wellness community — has not been formally bridged by randomized controlled trials. This evidentiary gap means clinicians and users must make decisions based on mechanism, animal data, and individual experience in the absence of definitive human trial evidence.
Reported Benefits
Accelerated musculoskeletal recovery is the primary reported benefit driving TB-500 use in athletic and performance medicine contexts. Anecdotal and case-based reports consistently describe faster resolution of tendon injuries (particularly Achilles tendinopathy, patellar tendinitis, and rotator cuff issues), muscle strains, ligament sprains, and joint inflammation. Many users report that injuries requiring weeks or months of standard conservative management resolve in significantly shorter timeframes when TB-500 is incorporated into the recovery protocol.
Anti-inflammatory effects appear to be a key mechanism behind TB-500's recovery benefits. By downregulating pro-inflammatory cytokines and promoting resolution of the inflammatory phase of healing, TB-500 may allow the tissue remodeling phase to begin more rapidly. This anti-inflammatory action is distinct from NSAIDs (which can impair healing if used chronically) — TB-500 appears to resolve inflammation rather than simply suppressing it, potentially resulting in better long-term tissue quality.
Cardiovascular and neurological protection represents an emerging area of TB-500 research. Animal studies have shown meaningful cardiac protection in models of heart attack, with reduced infarct size and improved functional recovery when TB-500 is administered peri-ischemia. Neurological studies suggest potential benefits in traumatic brain injury and neurodegenerative conditions. While these applications are far from clinical readiness for general use, they expand the potential therapeutic landscape of this peptide beyond orthopedic recovery.
Dosing Protocols
The most commonly referenced TB-500 protocol for acute injury recovery uses a loading phase followed by a maintenance phase. The loading phase involves 2–2.5mg administered twice weekly (total 4–5mg per week) for 4–6 weeks, with injections typically spaced 3–4 days apart. This aggressive initial dosing is intended to saturate tissue receptors and establish a therapeutic level during the active healing process when the demand for Thymosin Beta-4 activity is highest.
Following the loading phase, a maintenance protocol of 2–2.5mg once weekly or even biweekly (every 2 weeks) is used to sustain repair signaling during the remodeling phase of tissue recovery. Some practitioners use a 4–6 week on / 4–6 week off cycling pattern for ongoing injury prevention and general recovery optimization, particularly in high-volume athletes subject to repetitive microtrauma. The total protocol duration varies significantly based on injury severity, individual response, and clinical judgment.
For general wellness and recovery optimization (rather than acute injury treatment), lower doses of 1–1.5mg once or twice weekly have been used. There is no formally validated "optimal" dose — the protocols in common use are empirically derived from animal study data extrapolated to human body weight and adjusted based on clinical observation. Always start at the lower end of the dose range and adjust based on individual response and tolerance.
Reconstitution Guide
TB-500 is supplied as a white lyophilized powder in sealed vials, typically 2mg or 5mg per vial. Reconstitution requires sterile bacteriostatic water (BAC water), which contains 0.9% benzyl alcohol as a preservative that extends the stability of the reconstituted solution. Using sterile water without preservative is not recommended for TB-500 as the reconstituted solution has a shorter usable life and greater contamination risk.
To reconstitute a 2mg vial: draw 1mL of BAC water into an insulin syringe, swab the rubber stopper of both the BAC water vial and TB-500 vial with alcohol, inject the BAC water slowly into the TB-500 vial by directing the stream against the glass wall (not directly onto the powder), gently swirl the vial until the powder is completely dissolved. This yields a 2mg/mL solution where 1 unit on an insulin syringe (0.01mL) = 0.02mg, and a full 100-unit (1mL) syringe = the full 2mg dose.
Reconstituted TB-500 with BAC water is stable refrigerated at 2–8°C for approximately 30 days. Always swab the stopper before each draw, use a new needle for each injection, and inspect for particulates before use. If reconstituting a 5mg vial for dose flexibility, 2.5mL of BAC water yields 2mg/mL; for a more concentrated solution, 1mL yields 5mg/mL (0.5mg per 0.1mL drawn). Calculate your target volume carefully based on your chosen concentration.
Half-Life & Pharmacokinetics
The plasma half-life of TB-500 following subcutaneous or intramuscular injection is relatively short — estimated in the range of 30 minutes to several hours based on pharmacokinetic modeling of Thymosin Beta-4 analogs. However, the short plasma half-life does not correspond to a short duration of biological effect. TB-500 appears to exert its regenerative effects through receptor-mediated signaling cascades that continue to operate long after the peptide has cleared from circulation, creating a "downstream effect" that outlasts measurable plasma concentrations.
This disconnect between pharmacokinetic half-life and pharmacodynamic duration is characteristic of many peptide-based regenerative agents and helps explain why relatively infrequent dosing (twice weekly during loading, once weekly for maintenance) appears sufficient to drive meaningful tissue repair. The cells and signaling pathways activated by each dose continue their work for days after the peptide itself has been cleared, allowing for accumulation of biological effect with each successive administration.
The route of administration influences local tissue concentrations. Intramuscular injection in or near the injured tissue may achieve higher local concentrations relevant to the specific repair site, while subcutaneous injection provides more systemic distribution. In practice, most users inject subcutaneously at a convenient site (abdomen, thigh) for systemic distribution, relying on the peptide's ability to home to sites of injury through cytokine gradients and upregulated receptor expression in damaged tissue.
Administration Methods
TB-500 can be administered via subcutaneous (SubQ) or intramuscular (IM) injection. Subcutaneous injection into the abdomen, thigh, or upper arm is the most common and convenient approach for most users. The technique is identical to insulin injection: pinch the skin, insert a fine-gauge needle (27–31G) at 45–90 degrees, inject slowly, withdraw. IM injection (typically into the deltoid or vastus lateralis) delivers the peptide more directly into muscle tissue and may be preferred for muscular injuries, though evidence for superiority over SubQ is limited.
Some practitioners advocate for peri-lesional injection — injecting directly at or near the site of injury — to maximize local concentrations at the repair site. This approach requires anatomical knowledge and carries higher technique-related risks (nerve or vessel injury if misplaced). For most users without specialized training, systemic SubQ injection is both safer and sufficiently effective, as TB-500 has demonstrated the ability to home to sites of injury through chemotactic mechanisms.
Regardless of injection site, proper aseptic technique is non-negotiable: alcohol-swab the injection site before injection, use a fresh sterile needle for each administration, dispose of sharps in an approved sharps container, and avoid reusing needles or syringes. Injection site reactions (mild redness, swelling, transient tenderness) are common and typically resolve within 24–48 hours. Rotating injection sites across the protocol duration prevents chronic local irritation and lipohypertrophy.
Side Effects & Contraindications
TB-500 has a generally favorable safety profile based on available animal studies and limited human experience. The most commonly reported adverse effects are local injection site reactions — transient redness, mild swelling, and brief discomfort at the injection site — which are typical of any subcutaneous peptide injection and resolve within 24–48 hours. Systemic reactions are uncommon but can include mild fatigue or lightheadedness shortly after injection in some users, which typically resolves within hours.
A theoretical concern specific to TB-500 relates to its pro-angiogenic and cell migration properties. In theory, a peptide that promotes cell proliferation and migration could potentially stimulate growth of pre-existing tumors or dysplastic tissue. This concern is entirely theoretical for TB-500 in humans — there is no clinical evidence of cancer promotion in any human study — but it represents a reasonable precautionary contraindication. Individuals with active cancer, a history of certain cancers, or known pre-malignant conditions should not use TB-500 without explicit oncological clearance.
Additional precautions include: avoid use during pregnancy (insufficient safety data; the peptide's cell proliferation effects are contraindicated during fetal development), caution in autoimmune conditions where modulation of immune cell migration could alter disease activity, and caution in individuals with a history of fibrotic conditions (pulmonary fibrosis, liver fibrosis) given TB-500's role in extracellular matrix remodeling. As with all research peptides, the absence of long-term human safety data means that users accept some degree of unknown risk — this should be openly discussed with a supervising physician.
Stacking Protocols
TB-500 is most commonly stacked with BPC-157, another regenerative peptide with complementary mechanisms. BPC-157 primarily promotes angiogenesis and growth factor upregulation through a different receptor pathway than TB-500, and the combination has become the de facto "recovery stack" in performance medicine circles. The rationale is that TB-500 drives cell migration and cytoskeletal organization while BPC-157 promotes new blood vessel formation and growth factor signaling — two complementary pillars of tissue repair. Typical combination dosing uses 2mg of each, twice weekly.
For athletes in heavy training, TB-500 is sometimes combined with growth hormone secretagogues (CJC-1295/ipamorelin, MK-677) to create a comprehensive recovery protocol that addresses both local tissue repair (TB-500) and systemic anabolic recovery (GH axis support). The addition of a GH secretagogue may enhance collagen synthesis and overall recovery capacity, potentially synergizing with TB-500's direct tissue repair effects. This combination is used empirically without formal trial validation.
For joint-specific recovery, TB-500 is sometimes used alongside HA (hyaluronic acid) injections or PRP (platelet-rich plasma) therapy administered directly into affected joints by physicians. While these are different modalities (local vs. systemic), the combination may address different aspects of joint pathology — TB-500 providing systemic repair signaling while local interventions address the joint microenvironment directly. Any combination involving invasive procedures requires physician involvement and should not be undertaken based solely on online protocols.
Storage & Stability
Lyophilized TB-500 powder is relatively stable and should be stored refrigerated at 2–8°C, protected from light and moisture. Under proper storage conditions, the dry powder maintains potency for 12–24 months from the manufacturer's production date. Freezing the lyophilized powder (at -20°C) can extend shelf life further but is generally unnecessary for normal use timelines. The powder is sensitive to moisture — always keep the vial cap tight and avoid exposing the powder to humid environments.
Once reconstituted with bacteriostatic water, TB-500 solution should be refrigerated at 2–8°C and used within 30 days. The benzyl alcohol in BAC water acts as a bacteriostatic agent that prevents microbial growth and extends usable life compared to sterile water. Before each use, visually inspect the solution — discard if cloudy, discolored, or if particulates are visible. Even if the solution appears clear, discard after 30 days regardless of visual appearance.
Temperature excursions should be minimized. If a reconstituted vial is accidentally left at room temperature (20–25°C) for up to 24 hours, it can generally be returned to refrigeration and used, though the total remaining shelf life should be considered shortened. Repeated temperature cycling (refrigerator → room temperature → refrigerator) degrades the peptide more rapidly than constant refrigeration. Mark each reconstituted vial with the date of reconstitution to track the 30-day window.
Legal Status & Availability
TB-500 does not have FDA approval for any indication in the United States. It is classified as a research peptide and is not approved for human use by any major regulatory body as of 2026. It is not a scheduled controlled substance, which means possession is generally not a criminal matter in the US for personal use — but its sale for human consumption is prohibited by the FDA. It is legally sold by peptide research companies as a "research chemical" with "not for human use" labeling, a regulatory gray area that is frequently navigated by the research peptide industry.
In many other countries — including the UK, Australia, Canada, and most of the EU — TB-500 also lacks regulatory approval. Australia's Therapeutic Goods Administration (TGA) has been particularly active in restricting peptide research chemicals and has targeted both domestic suppliers and importers. Athletes subject to competitive drug testing should be aware that TB-500 is prohibited by WADA (World Anti-Doping Agency) and most national anti-doping bodies, with detection possible via urine and blood testing.
Obtaining TB-500 through a licensed compounding pharmacy with a physician prescription is possible in some jurisdictions and represents the most legally sound and quality-assured pathway. Peptides purchased from online research chemical vendors vary enormously in purity, concentration, and sterility — mass spectrometry testing of commercially available research peptides has revealed significant discrepancies between labeled and actual contents. Quality sourcing is a critical and often underappreciated aspect of peptide safety.
Bloodwork & Monitoring
While TB-500 does not directly affect standard metabolic parameters in the way that hormonal peptides do, baseline and periodic bloodwork is still recommended for anyone using it, particularly for extended protocols. A pre-protocol baseline should include: complete blood count (CBC) to establish hematological baseline, comprehensive metabolic panel (CMP) for liver and kidney function, inflammatory markers (CRP, ESR) if tracking injury-related inflammation as an outcome measure, and any injury-specific imaging (MRI, ultrasound) to document baseline pathology and later assess healing response.
Liver function tests (ALT, AST, GGT) should be monitored periodically during TB-500 use, as the liver is the primary site of peptide metabolism and clearance. Most users do not experience liver enzyme elevations, but establishing a baseline allows for early detection of any idiosyncratic hepatic response. Kidney function (creatinine, eGFR) monitoring is particularly important for users who are also taking NSAIDs, other nephrotoxic compounds, or who have pre-existing renal compromise.
Injury progress monitoring using functional assessments and imaging is arguably more clinically relevant for TB-500 than standard bloodwork. Tracking pain scores, range of motion, functional capacity (return to sport benchmarks), and serial imaging at 4–8 week intervals provides objective data on treatment response and helps guide decisions about protocol duration and dose adjustment. This outcome tracking also builds the case-based evidence that, in aggregate, contributes to the growing understanding of TB-500's efficacy in human musculoskeletal recovery.
Track TB-500 with Dosi
Log doses, track recovery protocols, and monitor progress with AI-powered guidance. Free to start.
Start Tracking Free →Educational use only. This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before using any compound.